ICER un­veils lat­est re­port on 'un­sup­port­ed' drug price in­creas­es

The drug pric­ing watch­dog known as the In­sti­tute for for Clin­i­cal and Eco­nom­ic Re­view on Mon­day un­veiled its an­nu­al re­port on what it says are drug price in­creas­es un­sup­port­ed by new clin­i­cal da­ta.

But some in the in­dus­try are push­ing back on the re­port, which pulls da­ta from 2021 and 2022. For Ab­b­Vie’s megablock­buster Hu­mi­ra (adal­i­mum­ab), for in­stance, biosim­i­lar com­pe­ti­tion has dri­ven the price down sig­nif­i­cant­ly since these in­creas­es were made.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER